BL-918 is a potent oral activator of UNC-51-like kinase 1 (ULK1) with an EC50 value of 24.14 nM and Kd value of 0.719 μM. BL-918 induces cell-protective autophagy and is used to treat Parkinson's disease.

 

Brand: BCM

 

Target: UNC-51-like kinase 1 (ULK1):24.14 nM(EC50)

 

Signaling Pathways: Autophagy

 

pKa: 11.13±0.70(Predicted)

 

Solubility: Soluble in DMSO; solublein Ethanol. Insoluble in Water.

 

Isomeric SMILES: C1=CC=C(C=C1)[C@H](C(=O)NC2=C(C=C(C=C2)F)F)NC(=S)NC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F  

 

InChIKey: BDBWQANRZRCMMD-LJQANCHMSA-N  

 

InChI: InChI=1S/C23H15F8N3OS/c24-15-6-7-18(17(25)11-15)33-20(35)19(12-4-2-1-3-5-12)34-21(36)32-16-9-13(22(26,27)28)8-14(10-16)23(29,30)31/h1-11,19H,(H,33,35)(H2,32,34,36)/t19-/m1/s1

 

Attribute
[Chem Name]	(2R)-2-[[3,5-bis(trifluoromethyl)phenyl]carbamothioylamino]-N-(2,4-difluorophenyl)-2-phenylacetamide
[Synonym]	BL-918; BL918; BL 918
[CAS No.]	2101517-69-3
[EINECS]	825-946-9
[MDL No.]	MFCD31693829
[Formula]	C23H15F8N3OS
[Molecular]	533.4369256
[Form]	A solid
[Storage]	Sealed in dry, 2-8°C

Goods Tag